Table 3 Comparison of clinical and laboratory characteristics between three groups according functional disability and disease activity.
From: Functional disability is related to serum chemerin levels in rheumatoid arthritis
Variables | Disabilityā+āhigh DAS28-ESR (nā=ā24) | Disabilityā+ālow DAS28-ESR (nā=ā19) | Non-disabled (nā=ā39) | p |
---|---|---|---|---|
Age (years) | 56Ā (35ā73) | 55 (37ā77) | 59 (30ā79) | 0.90 |
Body mass index | 28 (19ā35) | 28 (22ā34) | 26 (19ā46) | 0.10 |
Disease duration (years) | 14 (0.1ā27) | 8 (1ā30) | 9 (0.1ā30) | 0.39 |
RF (IU/mL) | 57 (8ā765) | 67 (9ā641) | 20 (5ā118) | 0.18 |
ESR (mm/h) | 33.5 (5ā354) | 24 (7ā45) | 21 (0.1ā43) | 0.06 |
Adipokines | ||||
Chemerin, (ng/mL) | 160 (77ā1402) | 136 (71ā235) | 112 (56ā277) | 0.008 |
Leptin, (ng/mL) | 31 (3ā115) | 25 (4ā175) | 33 (7ā99) | 0.98 |
Adiponectin, (ng/mL) | 7767 (1328ā25,529) | 12,886 (3921ā17,166) | 8927 (1368ā24,532) | 0.33 |
Resistin, (pg/mL) | 7 (2ā13) | 7 (4ā10) | 6 (4ā20) | 0.29 |
Visfatin, (ng/mL) | 19 (2ā172) | 21 (6ā255) | 20 (2ā278) | 0.87 |
Cytokines | ||||
IL-6, (pg/mL) | 7 (1ā110) | 6 (1ā32) | 4 (0.4ā29) | 0.10 |
TNF-α , (pg/mL) | 6 (1ā474) | 6 (3ā714) | 5 (0.3ā668) | 0.18 |
IL-1β, (pg/mL) | 7 (5ā11) | 7 (1ā9) | 7 (5ā15) | 0.87 |
IL-18, (pg/mL) | 389 (137ā1027) | 333 (141ā672) | 388 (127ā1767) | 0.60 |
Adhesion cell molecule | ||||
E-Selectin, (pg/mL) | 48 (32ā84) | 39 (9ā84) | 40 (13ā84) | 0.12 |
Treatment | ||||
Methotrexate, n (%) | 11 (46) | 9 (47) | 26 (67) | 0.22 |
Sulfasalazine, n (%) | 9 (38) | 11 (58) | 17 (44) | 0.30 |
Chloroquine, n (%) | 6 (25) | 3 (16) | 11 (28) | 0.64 |
Azathioprine, n (%) | 4 (17) | 3 (16) | 3 (8) | 0.47 |
b-DMARDs, n (%) | 6 (25) | 3 (16) | 4 (10) | 0.13 |
Corticosteroid, n (%) | 21 (88) | 18 (95) | 19 (49) | 0.008 |
Prednisone doses, mg/day | 5 (2.5ā10) | 5(2.5ā7.5) | 5 (2.5ā10) | 0.30 |